Repeat liver resection for recurrent intrahepatic cholangiocarcinoma: meta-analysis.


Journal

The British journal of surgery
ISSN: 1365-2168
Titre abrégé: Br J Surg
Pays: England
ID NLM: 0372553

Informations de publication

Date de publication:
14 06 2022
Historique:
received: 19 05 2021
accepted: 23 02 2022
pubmed: 29 4 2022
medline: 18 6 2022
entrez: 28 4 2022
Statut: ppublish

Résumé

Intrahepatic cholangiocarcinoma (ICC) is a relatively rare malignancy. The aim of this meta-analysis was to evaluate outcomes of repeat liver resection and non-surgical approaches for treatment of recurrent ICC. PubMed, Embase, and Web of Science databases were searched from their inception until March 2021 for studies of patients with recurrent ICC. Studies not published in English were excluded. Two meta-analyses were performed: a single-arm meta-analysis of studies reporting pooled short- and long-term outcomes after repeat liver resection for recurrent ICC (meta-analysis A), and a meta-analysis of studies comparing 1-, 3-, and 5-year overall survival (OS) rates after repeat liver resection and non-surgical approaches for recurrent ICC (meta-analysis B). Of 543 articles retrieved in the search, 28 were eligible for inclusion. Twenty-four studies (390 patients) were included in meta-analysis A and nine studies (591 patients) in meta-analysis B. After repeat liver resection, 1-, 3-, and 5-year OS rates were 87 (95 per cent c.i. 81 to 91), 58 (48 to 68), and 39 (29 to 50) per cent respectively. The 1-, 3-, and 5-year OS rates were higher after repeat liver resection than without surgery: odds ratio 2.70 (95 per cent c.i. 1.28 to 5.68), 2.89 (1.15 to 7.27), and 5.91 (1.59, 21.90) respectively. Repeat liver resection is a suitable strategy for recurrent ICC in selected patients. It improves short- and long-term outcomes compared with non-surgical treatments.

Sections du résumé

BACKGROUND
Intrahepatic cholangiocarcinoma (ICC) is a relatively rare malignancy. The aim of this meta-analysis was to evaluate outcomes of repeat liver resection and non-surgical approaches for treatment of recurrent ICC.
METHODS
PubMed, Embase, and Web of Science databases were searched from their inception until March 2021 for studies of patients with recurrent ICC. Studies not published in English were excluded. Two meta-analyses were performed: a single-arm meta-analysis of studies reporting pooled short- and long-term outcomes after repeat liver resection for recurrent ICC (meta-analysis A), and a meta-analysis of studies comparing 1-, 3-, and 5-year overall survival (OS) rates after repeat liver resection and non-surgical approaches for recurrent ICC (meta-analysis B).
RESULTS
Of 543 articles retrieved in the search, 28 were eligible for inclusion. Twenty-four studies (390 patients) were included in meta-analysis A and nine studies (591 patients) in meta-analysis B. After repeat liver resection, 1-, 3-, and 5-year OS rates were 87 (95 per cent c.i. 81 to 91), 58 (48 to 68), and 39 (29 to 50) per cent respectively. The 1-, 3-, and 5-year OS rates were higher after repeat liver resection than without surgery: odds ratio 2.70 (95 per cent c.i. 1.28 to 5.68), 2.89 (1.15 to 7.27), and 5.91 (1.59, 21.90) respectively.
CONCLUSION
Repeat liver resection is a suitable strategy for recurrent ICC in selected patients. It improves short- and long-term outcomes compared with non-surgical treatments.

Identifiants

pubmed: 35482020
pii: 6575275
doi: 10.1093/bjs/znac075
doi:

Types de publication

Journal Article Meta-Analysis

Langues

eng

Sous-ensembles de citation

IM

Pagination

580-587

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of BJS Society Ltd. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Ali Ramouz (A)

Department of General, Visceral, and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.

Sadeq Ali-Hasan-Al-Saegh (S)

Department of General, Visceral, and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.

Saeed Shafiei (S)

Department of General, Visceral, and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.

Sanam Fakour (S)

Department of General, Visceral, and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.

Elias Khajeh (E)

Department of General, Visceral, and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.

Ali Majlesara (A)

Department of General, Visceral, and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.

Ali Adeliansedehi (A)

Department of General, Visceral, and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.

Pascal Probst (P)

Department of General, Visceral, and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Study Centre of the German Surgical Society (SDGC), University Hospital Heidelberg, Heidelberg, Germany.

Christoph Springfeld (C)

Liver Cancer Centre Heidelberg (LCCH), University Hospital Heidelberg, Heidelberg, Germany.
Department of Medical Oncology, Heidelberg University Hospital, Heidelberg, Germany.

De-Hua Chang (DH)

Liver Cancer Centre Heidelberg (LCCH), University Hospital Heidelberg, Heidelberg, Germany.
Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany.

Christian Rupp (C)

Liver Cancer Centre Heidelberg (LCCH), University Hospital Heidelberg, Heidelberg, Germany.
Department of Gastroenterology and Hepatology, University Hospital Heidelberg, Heidelberg, Germany.

Carlos Carvalho (C)

Digestive Cancer Unit, Champalimaud Foundation, Lisbon, Portugal.

Mohammad Golriz (M)

Department of General, Visceral, and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Liver Cancer Centre Heidelberg (LCCH), University Hospital Heidelberg, Heidelberg, Germany.

Katrin Hoffmann (K)

Department of General, Visceral, and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Liver Cancer Centre Heidelberg (LCCH), University Hospital Heidelberg, Heidelberg, Germany.

Arianeb Mehrabi (A)

Department of General, Visceral, and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Liver Cancer Centre Heidelberg (LCCH), University Hospital Heidelberg, Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH